

NOTIFICATION AND FORM FOR ADVANCE VOTING

Notification and form for advance voting by postal voting in accordance with section 3 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations.

The notification and form should be at ExpreS2ion Biotech Holding AB disposal no later than 17 September 2020

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, at the extra general meeting on 23 September 2020. The voting right is exercised in accordance with the below marked voting options.

Name of shareholder	Personal ID number / date of birth/Registration number
Telephone number	Telephone number
Place and date	
Signature*	
Clarification of signature	

* In case of signing on behalf of a legal entity, the name of the signatory shall be printed next to the signature and an up-to-date certificate of registration (or a similar document) shall be attached to the proxy form.

Instructions to vote in advance:

Complete the shareholder information above

- Select the preferred voting options below
- Print, sign and send the form in the original to Baker & McKenzie Advokatbyrå, Attn: Ian Gulam, Box 180, 101 23 Stockholm. A completed and signed form may also be submitted electronically and shall, in that case, be sent to ian.gulam@bakermckenzie.com
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. The same applies if the shareholder votes in advance by proxy
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting
- If a shareholder does not intend to exercise its voting right by way of advance voting, the form for advance voting should not be submitted

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or

conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorization documentation, shall be provided to ExpreS2ion Biotech Holding AB no later than 17 September 2020. An advance vote can be withdrawn up to and including 17 September 2020 by contacting the company via ian.gulam@bakermckenzie.com. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the general meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on ExpreS2ion Biotech Holding AB's webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Extra general meeting in ExpreS2ion Biotech Holding AB on 23 September 2020

The options below comprise the proposals which are included in the notice convening the extra general meeting.

3. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination of whether the general meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Resolution regarding amendments of the company's articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Resolution regarding approval of the board of directors' resolution for rights issue Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Resolution to implement a warrant based incentive program for senior executives
8A. Resolution to issue warrants of series 2020/2024:1 Yes <input type="checkbox"/> No <input type="checkbox"/>
8B. Resolution on approval of transfer of warrants of series 2020/2024:1 to senior executives Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Resolution regarding board remuneration Yes <input type="checkbox"/> No <input type="checkbox"/>